Compass Q3 Loss Widens to $27.2M as Tovecimig Manufacturing Spend Jumps; $163M Cash Runs Into 2028
CMPX is trading near its 52-week low of $0.671 (13% above the low).
Summary
Compass posted a $27.2 million Q3 2026 net loss versus $14.3 million a year ago, with R&D up 72% on tovecimig manufacturing costs. Cash of $163 million is expected to fund operations into 2028, and no ATM shares were sold in the first nine months of 2026.
Key Events · Earnings and Guidance · CMPX
-
Q3 Loss Nearly Doubles
Net loss was $27.2 million for the three months ended September 30, 2026, versus $14.3 million in the prior-year quarter; nine-month loss reached $70.6 million versus $50.8 million.
-
Tovecimig Manufacturing Drives R&D
R&D rose 72% to $22.0 million in Q3, primarily from $8.6 million of tovecimig manufacturing costs; nine-month R&D was $55.0 million, up $12.7 million.
-
Cash Runway Into 2028
Cash, cash equivalents and marketable securities totaled $163 million at September 30, 2026, which management expects to fund operating expenses and capital expenditures into 2028.
-
No ATM Shares Sold
Under the December 2025 sales agreement with Leerink and Cantor Fitzgerald, the company sold no shares of common stock in the first nine months of 2026.
Analysis · CMPX · Life Sciences
The quarter's loss nearly doubled to $27.2 million from $14.3 million a year ago, driven mostly by $8.6 million of tovecimig manufacturing costs as the company builds drug supply ahead of a BLA it has not yet been cleared to file. That spending is a bet on approval, and the FDA's September recommendation for a new survival trial is the risk hanging over it. Against that, $163 million of cash and securities funds operations into 2028, so there is no near-term financing need and no ATM usage in the first nine months of 2026 — the dilution risk is deferred, not eliminated.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMPX was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $136.7M. The 52-week trading range was $0.67 to $6.88. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.